Recognition and treatment of peri-implant mucositis: Do we have the right perception? A structured review

Peri-implant mucositis is a common inflammatory lesion of the soft tissues surrounding endosseous implants, with no loss of the supporting bone. Its prevention or early diagnosis are vital for dental implant success.The aim of this review was to investigate knowledge strengths and gaps in clinicians' perceptions of periimplant mucositis prevalence and evidence for successful treatment.A literature search for articles published until 2020, reporting on the prevalence of peri-implant mucositis and its treatment was performed in standard online databases. The inclusion criteria were as follows: studies in English; studies with an available abstract; studies on humans with at least 1 dental implant; and studies reporting on the prevalence and/or treatment of peri-implant mucositis. Sixty-five studies fulfilled the inclusion criteria. The included papers were analyzed to identify data on the prevalence and treatment of peri-implant mucositis. The prevalence statistics for peri-implant mucositis had wide ranges in both the patient-based (PB) analysis and the implant-based (IB) analysis; the possible reasons for these wide ranges are discussed. Treatment methods for peri-implant mucositis were analyzed individually and compared to the management of gingivitis.It was determined that the currently available information on the prevalence rates and the standardized therapeutic protocols for peri-implant mucositis are insufficient. Since the mean gingivitis and peri-implant mucositis prevalence rates in the PB analysis were similar, it is possible that peri-implant mucositis is underestimated due to variables related to implant rehabilitation itself

Milk Products in Bread Making

The topic was the usage of milk in bread making. Initial investigations in bread making using milk were aimed at learning how to prepare milk best suited for bread making and finding the proper quantities for optimum results. The convenience, economy, and uniformity of dry milk solids greatly increased their usage by bakers. These advantages have been further augmented by research and experimentation by the dry milk producers, which have resulted in a product which would appreciably improve bread quality. Milk may be altered both in physical and chemical properties by heating. The article goes on to give more information on milk usage in baking

A bolometric measurement of the antineutrino mass

High statistics calorimetric measurements of the beta spectrum of 187Re are being performed with arrays of silver perrhenate crystals operated at low temperature. After a modification of the experimental set-up, which allowed to substantially reduce the background of spurious counts and therefore to increase the sensitivity on the electron antineutrino mass, a new measurement with 10 silver perrhenate microbolometers is running since July 2002. The crystals have masses between 250 and 350 micrograms and their average FWHM energy resolution, constantly monitored by means of fluorescence X-rays, is of 28.3 eV at the beta end-point. The Kurie plot collected during 4485 hours x mg effective running time has an end-point energy of 2466.1 +/- 0.8{stat} +/- 1.5 {syst} eV, while the half lifetime of the decay is found to be 43.2 +/- 0.2{stat} +/- 0.1{syst} Gy. These values are the most precise obtained so far for 187Re. From the fit of the Kurie plot we can deduce a value for the squared electron antineutrino mass m(nu)^2 of 147 +/- 237{stat} +/- 90{syst} eV^2. The corresponding 90% C.L. upper limit for m(nu) is 21.7 eV.Comment: 3 pages, 3 figures. Submitted to Phys. Rev. Let

Randomized placebo-controlled trial comparing desloratadine and montelukast in monotherapy and desloratadine plus montelukast in combined therapy for chronic idiopathic urticaria

BACKGROUND: H 1 -receptor antagonists are considered to be particularly effective in reducing pruritus, and they are therefore recommended as first-line treatment in patients with chronic idiopathic urticaria (CIU). Recently, antileukotriene receptors have been used in patients with CIU, either administered as monotherapy or combined with H 1 -receptor antagonists. OBJECTIVE: We compared the clinical efficacy of 5 mg of desloratadine administered once daily either as monotherapy or combined with a leukotriene antagonist, 10 mg of montelukast daily, and 10 mg of montelukast administered daily as monotherapy for the treatment of patients affected by CIU with placebo. METHODS: One hundred sixty patients aged 18 to 69 years (mean +/- SD, 43.9 +/- 13.4 years) with a history of moderate CIU were selected. A randomized, double-blind, double-dummy, placebo-controlled, parallel-group study design was used. Patients were treated with 5 mg of desloratadine once daily (n = 40), 10 mg of montelukast once daily (n = 40), 5 mg of desloratadine (n = 40) in the morning plus montelukast in the evening, or matched placebo (n = 40). Assessment of treatment efficacy was based on scores of daily cutaneous symptoms evaluated reflectively and instantaneously. RESULTS: Only the group treated with desloratadine as monotherapy or as combined therapy concluded the whole study. Twenty-seven of the 40 patients in the montelukast group and 35 of the 40 patients in the placebo group discontinued the treatment. As reflective evaluation, all groups showed significant differences compared with the placebo group in terms of total symptom score, number of hives, and size of largest hive. In addition to the pruritus, only the groups treated with desloratadine as monotherapy or combined therapy showed significant differences compared with those receiving placebo, whereas there were no differences between the montelukast and placebo groups. Finally, no differences were found between the desloratadine group and the desloratadine plus montelukast group. The instantaneous evaluation demonstrated similar results regarding the desloratadine group and the desloratadine plus montelukast group versus the placebo group, whereas there were no significant differences between the group treated with montelukast alone and the placebo group for pruritus and size of largest hive. No differences were found between the group treated with desloratadine alone and the desloratadine plus montelukast group. CONCLUSIONS: The results of this comparative study demonstrate that desloratadine is highly effective for the treatment of patients affected by CIU. In addition, the regular combined therapy of desloratadine plus montelukast does not seem to offer a substantial advantage with respect to desloratadine as monotherapy in patients affected by moderate CIU

RELAZIONE TRA HANDGRIP E FAMILIARITÀ AL DIABETE DI TIPO 2: UNO STUDIO PILOTA/ RELATIONSHIP BETWEEN TYPE 2 DIABETES AND HANDGRIP: RESULTS OF A PILOT STUDY

Obiettivo: È stata analizzata la possibile relazione, su un campione della popolazione siciliana, tra il grado di familiarità al diabete di tipo 2, i parametri antropometrici ed alcuni test di forza specifica. Materiali e metodi: In modalità random sono stati selezionati 88 uomini e 27 donne, distinti in FH- (assenza di familiarità per il diabete di tipo 2), FH+ (con un componente in linea indiretta con la malattia) ed FH++ (con un genitore affetto dalla malattia). Sono stati rilevati i parametri antropometrici, i parametri cardiovascolari ed è stato rilevato l’handgrip ad entrambe le mani. Le differenze tra i gruppi sono state analizzate con il test ANOVA ed attraverso correlazioni parametriche abbiamo verificato eventuali associazioni (Pearson). Risultati: È emerso che uomini e donne FH++ tendono ad avere un significativo incremento dell’indice di massa corporea (p<0,05) associato ad un incremento statisticamente significativo dei valori basali di pressione arteriosa diastolica (p<0,05). Non sono emerse differenze statisticamente significative tra i gruppi (FH- vs FH+ vs FH++) relativamente ai valori di handgrip espressi dalla mano destra e sinistra, in valore assoluto e relativo. Dallo studio delle correlazioni emerge una importante influenza del peso corporeo sul rendimento dei soggetti al test dell’handgrip (>.40). Conclusioni: La familiarità diretta al diabete di tipo 2 si correla con degli incrementi statisticamente significativi del peso corporeo e dei valori pressori cardiovascolari, indicando che questa popolazione risulta essere maggiormente a rischio per l’evoluzione della stessa malattia. Progetti di prevenzione sono auspicabili in tal senso. L’handgrip risulta essere fortemente correlato ai parametri antropometrici, pertanto indirettamente anche con la familiarità alla malattia. Un’estensione dello studio è auspicabile, al fine di poter meglio comprendere i fenomeni.Objectives: the purpose of this study was to analyze the relationship between family history to type 2 diabetes, anthropometrics characteristics and some fitness tests. Materials and methods: we randomly selected 88 men and 27 women, distinguishing on FH- (absence of family history to type 2 diabetes), on FH+ (with a familiar component with disease) and FH++ (with parent affected to diabetes). We recorded anthropometric parameters, basal blood pressure values and handgrip of both hands. The differences between the groups were analyzed with ANOVA test and Pearson’s correlation. Results: participants FH++ of both sexes showed a statistically significant increase of body mass index (p<0,05) and a significant increase of basal diastolic blood pressure (p<0,05). No family history-related differences were found on handgrip results in absolute and relative values, but the lower numbers of subgroups might have affected the statistical analysis. Correlation analysis showed that parameters like body weight, body mass index and body surface area are able to influence the handgrip test of both hands. Conclusion: family history to type 2 diabetes is strongly related to body weight and basal blood pressure values, confirming that FH++ participants have a major risk to develop disease compared to FH- participants. Handgrip test is strongly related to anthropometric parameters. The sample size represents the major limit of the study. More data are needed to confirm the association between variables

Autism spectrum disorder in Italy: demand for an integrated epidemiological surveillance system.

Autism spectrum disorder (ASD) is a complex neurodevelopmental syndrome of emerging public health concern, according to a documented significant increase of diagnosed cases of ASD in Europe and USA. In Italy, actually, it is not possible to estimate at national level a reliable ASD occurrence by using existing health and scholastic data flows. The lack of information has implications on social and healthcare services dedicated to subjects affected by ADS. The database of the Italian institute in charge of social and security assistance was accessed at the provincial level to investigate the ASD cases occurred in the Palermo province. The official reports of all subjects visited in 2013 by INPS physicians were analyzed by using an automatic software and diagnosis consistent with ASD were ex- tracted and flagged. Our findings support the choice of alternative use of INPS administrative database in order to define a reliable ASD occurrence estimate as first step to develop an integrated epidemiological surveillance system on AS

Monitoraggio in tempo reale dello stress idrico del pesco

La frutticoltura odierna è sempre più caratterizzata dall’utilizzo di nuove tecnologie che si basano sull’utilizzo di molteplici sensori. Una delle grandi sfide della Smart Agriculture (agricoltura intelligente) è quella di integrare le informazioni provenienti da sensori remoti, prossimali e a contatto in modelli informativi in grado di sostenere gli agricoltori, in modo tale da determinare un sostanziale beneficio economico per le aziende. La complessità delle informazioni ottenute scoraggia l’integrazione di dati apparentemente molto diversi, ma allo stesso tempo apre le porte a nuovi modelli d’impresa. In questo lavoro vengono messi in risalto alcuni vantaggi e difficoltà dell’utilizzo congiunto di sensori su foglie e frutti di nettarine

Randomized placebo-controlled trial comparing fluticasone aqueous nasal spray in mono-therapy, fluticasone plus cetirizine, fluticasone plus montelukast and cetirizine plus montelukast for seasonal allergic rhinitis

BACKGROUND: Corticosteroids are considered to be particularly effective in reducing nasal congestion and are therefore recommended as first-line treatment in allergic rhinitis patients with moderate to severe and/or persistent symptoms. OBJECTIVE: We compared the clinical efficacy of fluticasone propionate aqueous nasal spray (FPANS) 200 microg given once daily, administered in mono-therapy or combined therapy with a H1 receptor antagonist (cetirizine, CTZ) or with a leukotriene antagonist (montelukast, MSK), and the combined therapy of CTZ plus MSK in the treatment of patients affected by allergic rhinitis to Parietaria during natural pollen exposure. In addition, we examined the effect of the treatment on eosinophil counts and eosinophil cationic protein (ECP) in nasal lavage performed at beginning of season, during season and at the end of the season. METHODS: One hundred patients aged 12-50 years (mean+/-SD 31.8+/-9.6) with a history of moderate to severe Parietaria pollen-induced seasonal allergic rhinitis were selected. A randomized, double-blind, double dummy, placebo (PLA)-controlled, parallel-group study design was used. Patients were treated FPANS 200 microg once daily (n=20) or with FPANS 200 microg once daily, plus CTZ (10 mg) in the morning (n=20), or with FPANS 200 microg once daily, plus MSK (10 mg) in the evening (n=20) or with CTZ (10 mg) in the morning plus MSK in the evening (n=20) or matched PLA (n=20). Assessment of efficacy was based on scores of daily nasal symptoms and on eosinophil counts and ECP in nasal lavage. RESULTS: All treatments showed significant differences (P<0.001) compared with PLA in terms of total symptom, rhinorrhea, sneezing and nasal itching scores. Concerning nasal congestion on waking and daily only the groups treated with FPANS in mono-therapy or in combined therapy showed significant differences compared with PLA. Comparing the group treated with FPANS alone and the groups treated with FPANS plus CTZ, we found significant differences for total symptom score (P=0.04) and for nasal itching (P=0.003). The comparison between FPANS plus CTZ and FPANS plus MSK showed significant difference for nasal itching (P=0.003). Finally, there were significant differences between the group treated with FPANS and the group treated with CTZ plus MSK for total symptom score (P=0.009), for nasal congestion on waking (P<0.001) and nasal congestion daily (P<0.001). Also the comparisons between the group treated with FPANS plus CTZ and the group treated with CTZ plus MSK demonstrated significant differences (P<0.001) for total symptom, for nasal congestion on waking and for nasal congestion on daily, for rhinorrhea (P=0.04) and for nasal itching (P=0.003) scores. Concerning the comparison between the group treated with FPANS plus MSK and the group treated with CTZ plus MSK we found significant differences for total symptom score (P=0.005), for nasal congestion on waking (P<0.001) and for nasal congestion on daily (P<0.001). No other differences were observed between the groups. Concerning blood eosinophil counts, significant differences were found between the treatments with FPANS in mono-therapy or in combined therapy with PLA group during and at the end of the season (P=0.0003 and P<0.0001, respectively). Concerning eosinophils and ECP in nasal lavage, all treatments showed significant differences (P<0.001) compared with PLA. Besides, there were significant differences (P<0.001) between the groups treated with FPANS alone or in combined therapy and the group treated with CTZ plus MSK. CONCLUSION: The results of this comparative study demonstrate that FPANS is highly effective for treating patients affected by allergic rhinitis, with efficacy exceeding that of CTZ plus MSK in combined therapy. In addition, the regular combined therapy of FPANS plus CTZ or plus MSK would not seem to offer substantial advantage with respect to FPANS in mono-therapy in patients affected by seasonal allergic rhinitis